Paige Butler

Paige Butler

Roni Shouval, MD, PhD

Researcher Spotlight: Roni Shouval, MD, PhD MEMORIAL SLOAN KETTERING CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies have been a transformative advancement in the treatment of large B-cell lymphomas. However, many patients still experience relapse after CAR T-cell therapy. Using…

Laurianne Scourzic, PhD

Researcher Spotlight: Laurianne Scourzic, PhD JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Dr. Joseph R. Bertino Memorial Scholar Cancer stem cells have been identified in a variety of tumor types, which contribute to the continuous repopulation of…

Robert Albero Gallego, PhD

Researcher Spotlight: Robert Albero Gallego, PhD COLUMBIA UNIVERSITY Angioimmunoblastic T-cell lymphomas (AITLs) areaggressive forms of blood cancer and are often resistant to conventional chemotherapy. Certainmutations have been to be very common in AITLs, including mutations in the TET2 and RHOA…

Owhofasa Agbedia, MBBS, MPH

Researcher Spotlight: Owhofasa Agbedia, MBBS, MPH UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Chimeric antigen receptor (CAR)-T cell therapies involve the re-engineering of a patient’s ownimmune cells to help them find and fight cancer cells within the body. This treatment…

Harsh Shah, DO

Researcher Spotlight: Harsh Shah, DO The University of Utah Stedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused…

Helen Ma, MD

Researcher Spotlight: Helen Ma, MDStephanie A. Gregory Distinguished Scholar THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Veterans who have been involved in combat over the last several decades have been potentially exposed to a variety of carcinogenic elements, such as…